NASDAQ:IMGN - ImmunoGen Stock Price, Forecast & News

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

ImmunoGen, Inc. (NASDAQ:IMGN) released its earnings results on Friday, November, 1st. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.04. The biotechnology company earned $13.30 million during the quarter, compared to analysts' expectations of $10.38 million. The business's revenue was up 22.0% on a year-over-year basis. During the same period last year, the business earned ($0.32) earnings per share. View ImmunoGen's Earnings History.

ImmunoGen is scheduled to release their next quarterly earnings announcement on Friday, February 14th 2020. View Earnings Estimates for ImmunoGen.

9 brokerages have issued 12 month target prices for ImmunoGen's stock. Their forecasts range from $2.50 to $9.00. On average, they expect ImmunoGen's share price to reach $4.28 in the next twelve months. This suggests that the stock has a possible downside of 6.1%. View Analyst Price Targets for ImmunoGen.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 1 sell rating, 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ImmunoGen.

News headlines about IMGN stock have trended very negative recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. ImmunoGen earned a news impact score of -3.8 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for ImmunoGen.

ImmunoGen saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 12,550,000 shares, an increase of 14.2% from the December 15th total of 10,990,000 shares. Based on an average daily trading volume, of 2,430,000 shares, the days-to-cover ratio is currently 5.2 days. Approximately 8.5% of the shares of the company are sold short. View ImmunoGen's Current Options Chain.

Some companies that are related to ImmunoGen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Immunomedics (IMMU), Micron Technology (MU), NVIDIA (NVDA), Seattle Genetics (SGEN), Pfizer (PFE), Exelixis (EXEL), Nektar Therapeutics (NKTR), Alibaba Group (BABA), Synergy Pharmaceuticals (SGYP) and Heron Therapeutics (HRTX).

ImmunoGen's stock is owned by a number of of retail and institutional investors. Top institutional investors include Arden Trust Co (0.01%). Company insiders that own ImmunoGen stock include Anna Berkenblit, Daniel M Junius, David Brannon Johnston, Mark Alan Goldberg, Mark J Enyedy, Richard J Gregory and Thomas Ryll. View Institutional Ownership Trends for ImmunoGen.

IMGN stock was sold by a variety of institutional investors in the last quarter, including Arden Trust Co. Company insiders that have sold ImmunoGen company stock in the last year include Mark J Enyedy and Thomas Ryll. View Insider Buying and Selling for ImmunoGen.

Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IMGN stock can currently be purchased for approximately $4.56.

ImmunoGen has a market capitalization of $682.63 million and generates $53.82 million in revenue each year. The biotechnology company earns $-168,840,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. ImmunoGen employs 296 workers across the globe.View Additional Information About ImmunoGen.

The official website for ImmunoGen is http://www.immunogen.com/.

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]